Plate Nº 77 · recorded October 10, 2026
Neuroscience & MindReported finding
Researchers identify brain 'brake' that quiets chronic pain in mice
A mouse study from WashU Medicine identifies mu opioid receptors in the locus coeruleus as biological brakes that suppress chronic nerve pain, hinting at targeted, non-addictive therapies.
By James Calloway3 min read568 words
In brief
- Study published August 17, 2026 in Current Biology (DOI: 10.1016/j.cub.2026.07.048) by Washington University School of Medicine in St. Louis
- Senior author Jordan McCall, PhD; co-first authors Chao-Cheng Kuo, PhD and Makenzie R. Norris
- Removing mu opioid receptors from locus coeruleus neurons increased pain sensitivity in mice with nerve injuries
- Restoring those receptors reversed the heightened pain response
- Funded by NIH grants R01NS117899, R01NS135401, F31NS124301 and F31DA065440, plus NSF grant DGE-2139839
August 17, 2026 — A small cluster of neurons deep in the brain can act as a biological brake that silences chronic nerve pain, according to a new mouse study from Washington University School of Medicine in St. Louis. The findings, published in Current Biology, identify mu opioid receptors in a region called the locus coeruleus as gatekeepers of pain signaling and point toward therapies that could relieve suffering without activating opioid receptors throughout the body.
What did the team discover?
The researchers focused on mu opioid receptors, the same molecular docking sites targeted by morphine and fentanyl. These receptors appear throughout the brain and spinal cord; when natural or synthetic opioids bind to them, pain signals fade. The team asked whether receptors confined to the locus coeruleus — the brain's main hub for alertness and stress — play a special role in controlling chronic neuropathic pain, the shooting, stabbing or burning sensations that arise from damaged nerve fibers.
"Millions of adults live with chronic neuropathic pain caused by nerve damage," said Jordan McCall, PhD, an associate professor in the Center for Clinical Pharmacology at WashU Medicine and the study's senior author. "The pain is difficult to treat, and traditional opioid medications bind to receptors throughout the entire body and brain, often leading to side effects, tolerance and addiction risk."
Under healthy conditions, the locus coeruleus helps suppress pain traveling through the spinal cord. After nerve injury, however, the same circuitry can flip into overdrive and help sustain chronic pain.
How does the locus coeruleus act as a gatekeeper?
To test the receptor's role, the team ran two key experiments in mice with nerve injuries:
- They removed mu opioid receptors specifically from locus coeruleus neurons. Those animals grew even more sensitive to touch and heat than mice whose locus coeruleus cells still carried the receptors.
- When the researchers restored the receptors to those same neurons, the heightened pain response reversed.
The team interprets the result as evidence that mu opioid receptors in the locus coeruleus normally restrain an overactive pain circuit. Chronic pain, they propose, may weaken that restraint, turning a brake into a broken switch.
Co-first authors Chao-Cheng Kuo, PhD, a postdoctoral research associate, and Makenzie R. Norris, a former graduate student, led the work with colleagues at WashU Medicine.
What could this mean for future pain treatments?
The discovery opens a possible route to drugs that act only on mu opioid receptors inside the locus coeruleus, leaving the rest of the nervous system untouched. "Understanding how localized receptors in the locus coeruleus act as gatekeepers could lead to more targeted, effective pain therapies with fewer risks," McCall said.
The team's next step is to find chemical or genetic ways to tweak activity in that region without engaging opioid receptors elsewhere. Neuropathic pain affects millions of adults and resists many existing drugs; diabetes, viral infections and physical compression of nerve fibers are among the common triggers.
Caveats
The experiments took place in mice, and whether the same mechanism operates in people remains untested. The study appeared on August 17, 2026 (DOI: 10.1016/j.cub.2026.07.048). Funding came from the National Institutes of Health (grants R01NS117899, R01NS135401, F31NS124301 and F31DA065440), the National Science Foundation (DGE-2139839), the McDonnell Center for Systems Neuroscience, the Department of Anesthesiology at WashU Medicine and the Rita Allen Foundation, with additional support from the Open Philanthropy Project.
via medicine.washu.edu (Original)
More from James Calloway
Show full bio
Staff writer covering marketplaces and e-commerce at SciBeat.
205 articles
Nearby plates
- 29% Off Opioids After One Year: Support Program Could Be NHS Value
- Protein p11 Amplifies Signals Across 24 Drug-Targeted Receptors, Study Finds
- Childhood Stress May Leave a Molecular 'Scar' That Reshapes the Adult Brain
- Quitting Alcohol May Prime the Brain for Relapse, Mouse Study Finds
- Women Report Pain More Often Than Men in 6-Million-Person Study